EUCTR2017-005019-15-FI进行中（未招募）1 期
A Phase II, single arm, multicenter open label trial to determine the safety and efficacy of tisagenlecleucel in pediatric patients with relapsed or refractory mature B-cell non-Hodgkin lymphoma (NHL) (BIANCA) - BIANCA
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1.Signed informed consent and assent forms if applicable must be obtained prior to participation in the study.
- •2.Histologically confirmed (local evaluation) mature B-cell non-Hodgkin lymphoma (B-cell NHL) including the following subtypes; Burkitt lymphoma (BL), diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma (PMBCL), gray zone lymphoma (GZL), and follicular lymphoma (FL).
- •a.Note: Subjects with bone marrow involvement of >25% lymphoma cells by bone marrow biopsy/aspirate evaluation, will be excluded. Patients with B-cell NHL associated with Nijmegen breakage syndrome will be allowed.
- •b.Sufficient formalin-fixed, paraffin-embedded (FFPE) tumor sample must be available for correlative analyses. A recent tumor sample obtained for the purpose of the study must be submitted, however if not clinically feasible, an archival tumor biopsy from the most recent relapse may be submitted instead. Excisional biopsies should be submitted wherever possible; in cases where this is not possible a core needle biopsy is allowed. Fine needle aspiration (FNA) is not suitable.
- •3.Patients <18 years of age and weighing at least 6 kg at the time of screening.
- •4.Patients who have relapsed after one or more prior therapies (can include allogeneic and autologous hematopoietic stem cell transplant) or are primary refractory (have not achieved a CR or PR after the first line of therapy).
- •5.Measurable disease by radiological criteria in all patients at the time of screening.
- •6.Karnofsky (age =16 years) or Lansky (age <16 years) performance status =60.
- •7.Adequate bone marrow reserve without transfusions (transfusion > 2 weeks prior to laboratory assessment is allowed) defined as:
- •a.Absolute neutrophil count (ANC) >1000/mm3
- •b.Absolute lymphocyte count (ALC) >300/mm3
- •c.absolute number of CD3+ T cells >150/mm3
- •d.Platelets =50000//mm3
- •e.Hemoglobin =8.0 g/dl
- •8.Adequate organ function:
- •a.a serum creatinine (sCR) based on gender/age as described in detail the protocol
- •b.AST (aspartate aminotransferase) and ALT (alanine aminotransferase) =5 times the upper limit of normal (ULN) for age.
- •c.Bilirubin <1.5 x ULN (for Gilbert’s Syndrome patients total bilirubin <4 mg/dL).
- •d.Adequate pulmonary function
- •i.Oxygen saturation of >91% on room air.
- •ii.No or mild dyspnea (=Grade 1)
- •9.Must have a leukapheresis material of non-mobilized cells accepted for manufacturing. Note: Leukapheresis material will not be shipped to or assessed for acceptance by the manufacturing site until documented confirmation of all other eligibility criteria is received.
- •Other protocol-defined inclusion criteria may apply.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 35
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Prior gene therapy or engineered T cell therapy
- •2.Prior treatment with any anti-CD19 therapy
- •3.Allogeneic hematopoietic stem cell transplant (HSCT) <3 months prior to screening and =4 months prior to infusion
- •4.Presence of grade 2 to 4 acute or extensive chronic graft-versus-host disease (GVHD) in patients who received prior allogeneic HSCT.
- •5.Prior diagnosis of malignancy other than study indication, and not disease free for 5 years
- •6.Active, uncontrolled infection despite treatment at screening
- •7.Presence of active or prior hepatitis B or C as indicated by serology. Repeat serology is required if the interval between serology performed at screening and tisagenlecleucel infusion exceeds 8 weeks.
- •8.Human Immunodeficiency Virus (HIV) positive test. Repeat serology is required if the interval between serology performed at screening and tisagenlecleucel infusion exceeds 8 weeks
- •9.Active neurological autoimmune or inflammatory disorders not related to B cell NHL (e.g., Guillain-Barre syndrome, Amyotrophic Lateral Sclerosis)
- •10.Active CNS involvement by malignancy. Note: Patients with history of CNS disease that have been effectively treated will be eligible.
- •11.Patients with B-cell NHL in the context of post-transplant lymphoproliferative disorders (PTLD) associated lymphomas.
- •12.Patients with concomitant genetic syndromes associated with bone marrow failure status such as patients with Fanconi anemia, Kostmann syndrome, Shwachman syndrome or any other known bone marrow failure syndrome. Note: Patients with Down syndrome will not be excluded.
- •13.Intolerance to the excipients of the tisagenlecleucel cell product
- •14.Cardiac disorder defined as:
- •a.Cardiac or cardiac repolarization abnormality, including any of the following:
- •i.History of myocardial infarction (MI), angina pectoris, or coronary artery bypass graft (CABG) within 6 months prior to starting study treatment
- •ii.Clinically significant cardiac arrhythmias (e.g., ventricular tachycardia), complete left bundle branch block, high-grade AV block (e.g., bifascicular block, Mobitz type II and third degree AV block)
- •b.LVEF <45% as determined by ECHO or MRA or MUGA
- •c.NYHA functional class III or IV
- •15.Subjects enrolled in this study are not permitted to participate in additional parallel investigational drug or device studies
- •16.Pregnant or nursing (lactating) women.
- •Note: Women of child-bearing potential must have a negative serum pregnancy test performed at screening, within 24 hours prior to leukapheresis, within 24 hours prior to lymphodepletion Serum or urine, within 24 hours prior to tisagenlecleucel infusion and at EOS.
- •17.Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception while taking study treatment and for at least 12 months after the tisagenlecleucel infusion and until CAR T-cells are no longer present by qPCR on two consecutive tests.
- •18.Sexually active males who do not agree to use a condom during intercourse while taking study treatment and for at least 12
研究者
相似试验
进行中（未招募）
1 期
A study to determine the safety and efficacy of tisagenlecleucel in children and adolescents with non-Hodgkin lymphoma (NHL)Pediatric and adolescents patients with CD19positive r/r mature B-cell NHL who have relapsed after one or more prior therapies or are primary refractory.MedDRA version: 20.0 Level: HLGT Classification code 10025320 Term: Lymphomas non-Hodgkin's B-cell System Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2017-005019-15-SEovartis Pharma AG35
进行中（未招募）
1 期
A study to determine the safety and efficacy of tisagenlecleucel in children and adolescents with non-Hodgkin lymphoma (NHL)pediatric and adolescents patients with CD19positive r/r mature B-cell NHL who have relapsed after one or more prior therapies or are primary refractory.MedDRA version: 20.0Level: HLGTClassification code 10025320Term: Lymphomas non-Hodgkin's B-cellSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2017-005019-15-DKovartis Pharma AG35
进行中（未招募）
1 期
Efficacy and safety of tisagenlecleucel in adult patients with refractory or relapsed follicular lymphomaAdult patients with refractory or relapsed follicular lymphomaMedDRA version: 20.0Level: HLTClassification code 10016903Term: Follicle centre lymphomas, follicular grade I, II, IIISystem Organ Class: 100000004851MedDRA version: 21.1Level: PTClassification code 10061170Term: Follicle centre lymphoma, follicular grade I, II, IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-004385-94-ATovartis Pharma AG113
进行中（未招募）
1 期
Efficacy and safety of tisagenlecleucel in adult patients with refractory or relapsed follicular lymphomaEUCTR2017-004385-94-DEovartis Pharma AG113
已完成
2 期
A Phase II, single arm, multicenter open label trial to determine the safety and efficacy of tisagenlecleucel in children and adolescents with non-Hodgkin lymphoma (NHL) (BIANCA)JPRN-jRCT1080224705ovartis Pharma. K.K.2